ClinicalTrials.gg
Enrolling by invitationNCT07123402TRD205Updated Aug 17, 2025

To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia

A Phase 2 interventional study of TRD205 tablets and TRD205 tablets in Chronic Postoperative Neuralgia, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 3 months after the study started (first participant enrolled Apr 2025, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.

Planned enrollment
12th of 30
184 · median 158
Started
2025
with 6 others
Phase 2
9 of 40
4 open now
Primary completion
2026-04
later than 4 of 15 live
Registered
33rd of 40
by date
Lead sponsor
1 of 40
Beijing Tide Pharmaceutical Co., Ltd

Among the 40 studies in Neuralgia with a site in China, this one is the 12th largest by planned enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 4 of the 15 other live ones, and was the 33rd registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

This is a phase II, multicenter ,randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of TRD205 tablets in the treatment of chronic postoperative neuralgia

Read the detailed description

This study used a placebo as a control to explore the efficacy, safety and pharmacokinetic characteristics of multiple administration of TRD205 tablets at different doses forchronic postoperative neuralgia .

03

Conditions studied

  • Chronic Postoperative Neuralgia

Browse trials for

Keywords

  • chronic postoperative neuralgia
  • TRD205
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 Years ≤ Age ≤ 80 years (calculated as time of signing ICF), both male and female.
  • Subject experienced pain following surgical procedures including Thyroid gland and Breast surgery, orthopedic surgery , thoracotomy Etc. (except neurosurgery, amputation, cesarean section).
  • Chronic pain ≥ 3 months post-op with pain localized to the operative site, Or The area of innervation that projects to the nerve at this site (Including radicular pain radiating to one side or limb after spinal surgery) Or involving the dermatome.
  • DN4 scale ≥ 4, AND The subject's pain was judged by the investigator to be neuropathic in nature.
  • Subjects had moderate to severe pain intensity (ie, averaged over the single-blind run-in period NRS Score ≥ 4 Points, see requirements for single-blind run-in period and randomization criteria for details).
  • The subject is able to communicate well with the investigators, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the form .
  • Subject is willing to voluntarily use the specified in the protocol from signing the ICF to 1 month after the last dose of drug (For details see Fig. 附录4) . Both male and female subjects had no plans to donate sperm or ova during the study and for 1 month after investigational product administration.

Exclusion criteria

Exclusion Criteria:

  • Investigator Judge the pain of subjects in whole or in part Pathological pain or pain in the central nervous system Caused by other postoperative complications (e.g., infection, disease recurrence, etc.).
  • Present Other Causally induced pain, such as the presence of skin disease in the affected skin area, cervical and lumbar spine disease, trauma, etc., thus affecting the investigator's evaluation of CPSNP or confusing the subject's self-assessment of CPSNP.
  • Presence of other neurological or psychiatric disorders that, in the judgment of the investigator, could confound the subject's self-assessment of CPSNP or affect the subject's ability to complete diary card completion.
  • Known history of to products or components or of rescue medication during the study period, or history of hypersensitivity to two or more drugs.
  • Previously Received Any prohibited medication or non-drug therapy, and in Fig. Single-Blind Run-in Period Pre Did not undergo the protocol-required (excluded medications Elution Phase: Single-Blind Run-in Period ≥ 5 half-lives or 7 days prior, whichever is longer; non-drug therapy is prohibited Elution Phase: Single-Blind Run-in Period ≥ 30 days prior) that may interfere with the evaluation of the test drug during the study.
  • Have an electrical stimulation instrument or intrathecal drug infusion system implanted to treat pain.
  • History of alcoholism (> 14 units/week of alcohol, 1 unit is equivalent to 360 mL of beer, or 45 mL of spirits with 40% alcohol, or 150 mL of wine) or drug abuse or drug abuse within 1 year prior to signing the ICF.
  • Patients with acute or chronic diseases or unstable diseases, such as but not limited to acute cardiovascular disease, cerebrovascular disease, liver, kidney, respiratory system, blood system, immune system and other diseases, inflammatory or rheumatic diseases, uncontrolled infection, untreated endocrine diseases, etc., and affecting the subjects at the investigator's discretion.
  • Present Dysphagia Or any gastrointestinal disorder affecting drug absorption.
  • diagnosed within 2 years prior to signing the ICF (with the exception of non- cutaneous basal cell or squamous cell carcinoma or carcinoma in situ of the cervix that has been appropriately treated or excised).
  • Patients with previous suicidal behavior or a positive response to Item 4 or 5 on the C-SSRS scale (for the 12 months prior to signing the ICF) .
  • Systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg; Systolic pressure ≤ 90 mmHg and/or diastolic pressure ≤ 60 mmHg; Heart rate \< 50 or > 110 beats per minute.
  • \< 1.5 × 10 9 /L; count \< 100 × 10 9 /L; (AST) > 2.0 × (ULN); alanine aminotransferase (ALT) > 2.0 × ULN; Urea or urea nitrogen (Urea or BUN) > 1.5 × ULN; Creatine kinase > 2.0 × ULN; Estimated serum \< 60 mL/min by Cockcroft-Gault formula.
  • Treponema pallidum antibody or antibody positive in any test at screening and judged by the investigator as not suitable for the subject .
  • Subjects who are expected to require reoperation from signing the ICF to the end of the study.
  • Females who are lactating or pregnant, or intend to become pregnant (female subjects or partners of male subjects) during the study period and within 1 month after dosing.
  • Those who have participated in or are participating in other clinical trials within 1 month prior to signing the ICF.
  • Other conditions not suitable for inclusion as judged by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    200mg treatment group

    Take TRD205 tables or placebo orally once a day every morning for 6 consecutive weeks

    Drug: TRD205 tablets

  • Experimental
    400mg treatment group

    Take TRD205 tables or placebo orally once a day every morning for 6 consecutive weeks

    Drug: TRD205 tablets

  • Experimental
    600mg treatment group

    Take TRD205 tables or placebo orally once a day every morning for 6 consecutive weeks

    Drug: TRD205 tablets

  • Placebo comparator
    Placebo

    Take placebo orally once a day every morning for 6 consecutive weeks

    Drug: Placebo

Interventions

  • orally ;Take TRD205 1 tablets and Placebo 2 tablets

  • orally ;Take TRD205 2 tablets and Placebo 1 tablets

  • orally ;Take TRD205 3 tablets and Placebo 0 tablets

  • DrugPlacebo

    orally ;Take Placebo 3 tablets

06

What researchers measure

Primary outcomes

  1. The change in the weekly average NRS (numeric pain rating scale,0~10:0 equated to no pain, and 10 equated to the worst pain imaginable )pain score from baseline after 6 weeks of treatment

    The Digital Assessment Scale (NRS) is used to evaluate the degree of pain in patients using the 11-point numeric pain rating scale (0-10; 0 equated to no pain, and 10 equated to the worst pain imaginable).The NRS pain score will be was assessed during the single-blind introduction period, the double-blind treatment period, and at the early end of the visit.The baseline of the NRS pain score is defined as the weekly average of the NRS pain score collected during the single-blind introduction period. Before taking the medicine every morning, the subjects retrospectively evaluated the average pain level in the past 24 hours. In addition, 1 hour before each remedial analgesia, the average pain intensity from the previous use of the investigational drug to the use of the remedial medication should be retrospectively assessed.NRS scores were collected at Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, and at the early end of the visit for the calculation of the weekly average score.

    Time frame: 8 weeks

Secondary outcomes

  1. Treatment-Related Adverse Events

    Assessment of all AEs, SAEs and TEAEs

    Time frame: 7 weeks

  2. Peak Plasma Concentration(Cmax)

    Two samples were collected before administration at Visvisit 7( the last administration) and within 1 to 4 hours after administration.The blood drug concentration data of TRD205 obtained in this study will be combined with the previously completed clinical research data for population pharmacokinetic analysis (using the nonlinear mixed-effects model \[NONMEM\]), and a population pharmacokinetic model will be established to characterize the PK characteristics of TRD205.Then, based on the parameter estimates of the established final population pharmacokinetic model, the individual exposure parameters of the subjects were estimated for further dose-effect (exposing-effect) analysis, including the correlation exploration analysis of PK/ efficacy and PK/ safety.

    Time frame: Within 4 hours after the last administration

  3. Area under the plasma concentration versus time curve (AUC)

    Two samples were collected before administration at Visvisit 7( the last administration) and within 1 to 4 hours after administration.The blood drug concentration data of TRD205 obtained in this study will be combined with the previously completed clinical research data for population pharmacokinetic analysis (using the nonlinear mixed-effects model \[NONMEM\]), and a population pharmacokinetic model will be established to characterize the PK characteristics of TRD205.Then, based on the parameter estimates of the established final population pharmacokinetic model, the individual exposure parameters of the subjects were estimated for further dose-effect (exposing-effect) analysis, including the correlation exploration analysis of PK/ efficacy and PK/ safety.

    Time frame: Within 4 hours after the last administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2026, 12 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 12 months is below that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 14, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Apr 20, 2026
CompletionEst.
May 27, 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123402
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Apr 9, 2025
Primary completion
Apr 20, 2026 (estimated)
Completion
May 27, 2026 (estimated)
Last update
Aug 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRD205

Start the discussion